Protocol Ledger

NCT06613685 · Phase II/III · TERMINATED

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Interventional Phase II/III clinical trial protocol NCT06613685 sponsored by Gilead Sciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-21 Enrollment: 73 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06613685
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)73 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06613685
Protocol FieldVerified Registry Value
NCT IdentifierNCT06613685
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment73 participants (ACTUAL)
Registered Start Date2024-10-21
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06613685
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI